Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Net Cash Flow (2022 - 2025)

Historic Net Cash Flow for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to -$18.2 million.

  • Stoke Therapeutics' Net Cash Flow rose 5823.29% to -$18.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.5 million, marking a year-over-year decrease of 6633.72%. This contributed to the annual value of -$63.2 million for FY2024, which is 18118.53% down from last year.
  • As of Q3 2025, Stoke Therapeutics' Net Cash Flow stood at -$18.2 million, which was up 5823.29% from -$173.3 million recorded in Q2 2025.
  • Over the past 5 years, Stoke Therapeutics' Net Cash Flow peaked at $146.8 million during Q1 2025, and registered a low of -$173.3 million during Q2 2025.
  • Its 4-year average for Net Cash Flow is -$4.1 million, with a median of -$2.1 million in 2023.
  • In the last 5 years, Stoke Therapeutics' Net Cash Flow tumbled by 198641.38% in 2024 and then skyrocketed by 124169.19% in 2025.
  • Stoke Therapeutics' Net Cash Flow (Quarter) stood at $160000.0 in 2022, then surged by 815.62% to $1.5 million in 2023, then crashed by 1588.46% to -$21.8 million in 2024, then grew by 16.76% to -$18.2 million in 2025.
  • Its last three reported values are -$18.2 million in Q3 2025, -$173.3 million for Q2 2025, and $146.8 million during Q1 2025.